AMENDMENTS TO THE CLAIMS:

1. (currently amended) A pharmaceutical formulation containing complexes of cationic liposomes constituted of phospholipids and polydeoxyribonucleotides having a molecular weight in the range ~~15,000-60,000 Da~~ 15,000-50,000, said polydeoxyribonucleotides obtained by depolymerization of nucleic acids, in the complexes the polydeoxyribonucleotides being located on the outer surface of the liposome wherein the weight ratio between the liposome amount and the polydeoxyribo-nucleotides ranges from 10:2 to 10:0.1.

2. (previously presented) The pharmaceutical formulation according to claim 1 having an anti-inflammatory activity.

3. (previously presented) The pharmaceutical formulation according to claim 1 having an anti-thrombotic activity.

4. (previously presented) The pharmaceutical formulation according to claim 1 having an anti-hypertensive activity.

5. (previously presented) The pharmaceutical formulation according to claim 1 for the therapy of pathologies the treatment of which requires a sustained release of the endothelial prostacyclin.

6. (previously presented) The pharmaceutical formulation according to claim 1 wherein the polydeoxyribonucleotide is defibrotide.

7. (previously presented) The pharmaceutical formulation according to claim 6 wherein the polydeoxyribonucleotide has a molecular weight in the range 15,000-30,000.

8. (previously presented) The pharmaceutical formulation according to claim 1 wherein one or more antioxidants are added.

9. (previously presented) The pharmaceutical formulation according to claim 1, wherein cationic surfactants containing one or more mono-, di-substituted amminic groups, or quaternary ammonium groups, are present, said quaternary ammonium groups containing one or more aliphatic chains with a number of carbon atoms ranging from 8 to 22.

10. (previously presented) The pharmaceutical formulation according to claim 1 wherein the molar ratio between the total amount of the liposome lipid(s) and a cationic surfactant ranges from 10:0.05 to 10:3.

11. (previously presented) The pharmaceutical formulation according to claim 10 wherein the phospholipids in the liposomes include phosphatidylcoline or phosphatidylethanolamine and a second and different lipid and the molar ratio of the phosphatidylocline or phosphatidylethanolamine: second lipid: cationic surfactant ranges from 9:1:0.05 to 7:3:3.

Claims 12-18 (canceled)

19. (previously added) A method for treating inflammation in a patient in need thereof, comprising administering to the patient an antiflammatory effective amount of the pharmaceutical formulation according to claim 1.

20. (previously added) A method for treating thrombosis in a patient in need thereof, comprising administering to the patient an antithrombotic effective amount of the pharmaceutical formulation according to claim 1.

21. (previously added) A method for treating hypertension in a patient in need thereof, comprising administering to the patient an antihypertensive effective amount of the pharmaceutical formulation according to claim 1.

22. (previously added) A method for providing a sustained release of endothelial prostacyclin in a patient in need thereof, comprising administering to the patient a sustained release providing effective amount of the pharmaceutical formulation according to claim 1.